Vivaglobin Related Published Studies
Well-designed clinical trials related to Vivaglobin (Immune Globulin Subcutaneous Human)
Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO):
a phase II double-blind placebo-controlled trial. [2014]
Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. [2011.08.01]
Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. [2010.06]
GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. [2009.07]
Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. [2008.11]
Intravenous immunoglobulins in the treatment of immune neuropathies. [2008.10]
Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii. [2008.10]
Sulphasalazine inhibits human antigen-specific immune responses in vivo. [2007.04]
Well-designed clinical trials possibly related to Vivaglobin (Immune Globulin Subcutaneous Human)
Efficacy and safety of sublingual immunotherapy for two seasons in patients with
Japanese cedar pollinosis. [2015]
Examination of the significant placebo effect in the treatment of interstitial
cystitis/bladder pain syndrome. [2014]
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. [2014]
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin
intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of
evolocumab. [2014]
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17
monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic
agents or had an inadequate response to tumor necrosis factor inhibitors. [2014]
Effect of reduced dose schedules and intramuscular injection of anthrax vaccine
adsorbed on immunological response and safety profile: a randomized trial. [2014]
Delaying skeletal-related events in a randomized phase 3 study of denosumab
versus zoledronic acid in patients with advanced cancer: an analysis of data from
patients with solid tumors. [2014]
Phase III study of the efficacy and safety of subcutaneous versus intravenous
tocilizumab monotherapy in patients with rheumatoid arthritis. [2014]
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo-
and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab
in subjects with hypercholesterolemia on background statin therapy. [2014]
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide,
for the prevention of frequent episodic migraine: a randomised, double-blind,
placebo-controlled, exploratory phase 2 trial. [2014]
Examination of the significant placebo effect in the treatment of interstitial
cystitis/bladder pain syndrome. [2014]
Subcutaneous tocilizumab versus placebo in combination with disease-modifying
antirheumatic drugs in patients with rheumatoid arthritis. [2014]
Evaluation of sex, race, body mass index and pre-vaccination serum progesterone
levels and post-vaccination serum anti-anthrax protective immunoglobulin G on
injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC
AVA human clinical trial. [2014]
Safety and efficacy of golimumab in Chinese patients with active ankylosing
spondylitis: 1-year results of a multicentre, randomized, double-blind,
placebo-controlled phase III trial. [2014]
Two year follow-up of clinical and inflammation parameters in children
monosensitized to mites undergoing subcutaneous and sublingual immunotherapy. [2013]
Comparison of three enthesitis indices in a multicentre, randomized,
placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). [2013]
Omalizumab is effective in allergic and nonallergic patients with nasal polyps
and asthma. [2013]
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 in combination with a statin in patients with
hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled,
dose-ranging, phase 2 study. [2012]
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 as monotherapy in patients with
hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled,
phase 2 study. [2012]
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol
levels in statin-intolerant patients: the GAUSS randomized trial. [2012]
Repeated low-dose intradermal allergen injection suppresses allergen-induced
cutaneous late responses. [2012]
Responder analysis of the effects of denosumab on bone mineral density in men
receiving androgen deprivation therapy for prostate cancer. [2012]
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis
irrespective of its anti-inflammatory effects: disassociation of the link between
inflammation and destruction. [2012]
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. [2012]
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. [2012]
Adalimumab induces and maintains mucosal healing in patients with Crohn's
disease: data from the EXTEND trial. [2012]
Immunology in the Clinic Review Series; focus on allergies: immunotherapy for
food allergy. [2012]
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis:
104-week results of the GO-RAISE study. [2012]
Evaluation of abatacept administered subcutaneously in adults with active
rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity,
efficacy and safety (phase Iiib ALLOW study). [2012]
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. [2011.09]
Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. [2011.08.30]
A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. [2011.08]
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. [2011.06]
Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. [2011.06]
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). [2011.05]
Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301, a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers. [2011.05]
Parenteral insulin suppresses T cell proliferation to islet antigens. [2011.05]
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. [2011.04]
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [2011.03.20]
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. [2011.03.05]
Assessment of short-term changes induced by a Dermatophagoides pteronyssinus extract on asthmatic patients. Randomised, double-blind, placebo-controlled trial. [2011.03]
Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. [2011.03]
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. [2011.03]
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. [2011.02.28]
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. [2011.02]
[Clinical efficacy and immunological changes in children with allergic rhinitis receiving specific immunotherapy with Dermatophagoides pteronyssinus]. [2011.01]
TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. [2011.01]
[A multicenter, double-blind, randomized, placebo-controlled clinical trial of
etanercept treatment of Chinese patients with active ankylosing spondylitis]. [Article in Chinese] [2011]
A 52-week trial comparing briakinumab with methotrexate in patients with
psoriasis. [2011]
SIT beyond respiratory diseases. [2011]
A randomized, double-blind, placebo-controlled, single-dose study to evaluate the
safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab
administered subcutaneously to postmenopausal Japanese women. [2011]
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to
IL-1R1) in patients with osteoarthritis of the knee. [2011]
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in
patients with H1-antihistamine-refractory chronic idiopathic urticaria. [2011]
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe
psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and
Korean patients (PEARL). [2011]
A double-blind placebo-controlled randomized trial of adalimumab in the treatment
of hidradenitis suppurativa. [2011]
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528,
a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a
studies in subjects with asthma. [2011]
Randomized, double-blind study of denosumab versus zoledronic acid in the
treatment of bone metastases in patients with advanced cancer (excluding breast
and prostate cancer) or multiple myeloma. [2011]
Long-term tolerance after allergen immunotherapy is accompanied by selective
persistence of blocking antibodies. [2011]
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. [2010.12.10]
Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. [2010.12]
Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. [2010.12]
Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. [2010.11]
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. [2010.10]
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. [2010.10]
Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. [2010.09]
Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial. [2010.09]
Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. [2010.09]
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. [2010.09]
Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. [2010.08]
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. [2010.08]
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. [2010.08]
Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. [2010.08]
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. [2010.07]
Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. [2010.07]
Clinical characteristics of oral tolerance induction of IgE-mediated and non-IgE-mediated food allergy using interferon gamma. [2010.07]
Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. [2010.07]
Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. [2010.07]
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. [2010.07]
Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. [2010.06]
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. [2010.06]
An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. [2010.06]
Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. [2010.06]
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. [2010.05.15]
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. [2010.05.10]
Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. [2010.05.01]
Treatment of hidradenitis suppurativa with etanercept injection. [2010.05]
Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. [2010.05]
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. [2010.05]
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. [2010.05]
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. [2010.04.15]
Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. [2010.04]
Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. [2010.04]
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. [2010.04]
|
